ADA/EASD guidelines: Where do the SIGNs send us? Are the messages NICE?
Following the publication of the ADA/EASD guidelines for the Management of Hyperglycaemia in Type 2 Diabetes at EASD in 2018, Dr Seidu explores how these guidelines should impact the management of diabetes in the UK? Do the guidelines support the recommendations from SIGN and what update is needed from NICE?
- A chance to see the newly published ADA/EASD guidelines
- How and why the guidelines were developed
- Recommendations on what should change in the UK as a result of these guidelines
- What is needed from NICE?
This session has been organised by Napp Pharma
Thursday 15th November 2018
10:05 - 10:35
Primary, Community & Specialist Care